List of Excipients in Branded Drug ELETRIPTAN HYDROBROMIDE

« Back to Dashboard

Generic Drugs Containing ELETRIPTAN HYDROBROMIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	eletriptan hydrobromide	0093-8310	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	eletriptan hydrobromide	0093-8310	CROSCARMELLOSE SODIUM
Teva Pharmaceuticals USA Inc	eletriptan hydrobromide	0093-8310	FD&C YELLOW NO. 6 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	eletriptan hydrobromide	0093-8310	HYPROMELLOSE 2910

What are the Most Frequently-Used Excipients in ELETRIPTAN HYDROBROMIDE?

# Of NDCs	Excipient
1	ALUMINUM OXIDE
4	ANHYDROUS LACTOSE
7	CELLULOSE, MICROCRYSTALLINE
14	CROSCARMELLOSE SODIUM

Eletriptan Hydrobromide Excipient Strategy and Commercial Opportunities

Last updated: October 4, 2026

Eletriptan hydrobromide is a mature, immediate-release oral small molecule marketed in the United States as Relpax 20 mg and 40 mg tablets. The core commercial opportunity is a low-complexity generic tablet with a robust excipient supply chain, not a difficult formulation platform. Differentiation is more likely through orally disintegrating, rapidly dispersible, pediatric-age-appropriate, or combination products than through conventional tablets.

The reference formulation uses standard direct-compression or dry-granulation excipients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, and triacetin.[1] A generic applicant can generally pursue a conventional immediate-release tablet using common compendial materials, subject to pharmaceutical equivalence, dissolution, stability, and bioequivalence requirements.

The strongest commercial positions are:

1. A low-cost 20 mg and 40 mg generic tablet.
2. A differentiated orally disintegrating tablet or rapidly dispersible tablet.
3. A formulation with improved swallowability and lower tablet mass.
4. A multi-product migraine portfolio incorporating eletriptan with an antiemetic or nonsteroidal anti-inflammatory drug, where regulatory and patent constraints permit.
5. Contract manufacturing or private-label supply for markets where branded triptan access remains limited.

What is eletriptan hydrobromide and how is it formulated?

Eletriptan hydrobromide is the hydrobromide salt of eletriptan, a selective 5-HT1B/1D receptor agonist used for the acute treatment of migraine with or without aura in adults.[1] The reference product is an immediate-release, film-coated tablet administered at 20 mg or 40 mg.

The formulation is not technically complex. It does not require a modified-release matrix, lipid vehicle, sterile process, device combination, or biologic manufacturing platform. The main formulation risks are dose uniformity, disintegration, dissolution, moisture control, and management of the active pharmaceutical ingredient's salt and particle properties.

Reference-product excipient profile

Component	Likely function in Relpax-type tablets	Commercial and technical relevance
Lactose monohydrate	Diluent and compressibility aid	Low cost, broad supplier base; avoid in patients with significant lactose intolerance only if clinically relevant
Microcrystalline cellulose	Diluent, dry binder, tablet-strength contributor	Supports direct compression and rapid disintegration
Croscarmellose sodium	Superdisintegrant	Controls tablet breakup and early dissolution
Magnesium stearate	Lubricant	Excessive concentration or blending can slow wetting and dissolution
Hypromellose	Film-forming coating polymer	Supports film integrity and identification
Titanium dioxide	Opacifier and pigment	Regulatory review differs by jurisdiction
Triacetin	Plasticizer in film coating	Improves coating flexibility and reduces cracking

The reference product's formulation establishes a practical Q1/Q2 development target, but an ANDA applicant does not necessarily need to duplicate every excipient quantitatively. The applicant must demonstrate pharmaceutical equivalence and bioequivalence, while the final formulation must meet quality, stability, impurity, and dissolution specifications.

What excipient strategy is most suitable for generic eletriptan tablets?

A conventional formulation should begin with a low-risk, compendial excipient system that supports rapid disintegration and consistent dissolution. A practical target is a lactose or microcrystalline-cellulose-based core with croscarmellose sodium as the primary superdisintegrant and magnesium stearate at the lowest level that provides acceptable ejection force.

Recommended formulation architecture

Formulation element	Preferred strategy	Key development issue
Diluent	Lactose monohydrate, microcrystalline cellulose, or a combination	Balance tablet hardness, disintegration, and powder flow
Binder	Microcrystalline cellulose or low-level copovidone if needed	Avoid excessive binding that delays disintegration
Disintegrant	Croscarmellose sodium, crospovidone, or sodium starch glycolate	Establish rapid breakup without capping or friability
Lubricant	Magnesium stearate	Optimize mixing time to avoid hydrophobic over-lubrication
Glidant	Colloidal silicon dioxide where needed	Improve flow without impairing content uniformity
Coating	Hypromellose-based aqueous film coat	Control moisture exposure and coating weight
Color system	Iron oxide or other jurisdictionally acceptable pigment	Maintain product identification and regulatory compliance

The most defensible initial approach is to retain the reference product's excipient classes where feasible. That reduces formulation risk, supports a familiar manufacturing process, and limits the number of variables in comparative dissolution and bioequivalence work.

A non-lactose formulation can provide a marketing advantage for selected patients and contract customers. Microcrystalline cellulose, mannitol, and crospovidone can support a lactose-free platform. That change, however, creates a new taste, mouthfeel, density, and compression profile. It should be justified by a clear commercial objective rather than treated as a technical improvement by default.

What formulation opportunities exist beyond standard tablets?

The highest-value formulation opportunities involve administration convenience. Eletriptan is used during acute migraine attacks, when nausea, vomiting, dysphagia, and delayed gastric emptying can reduce the practicality of conventional tablets.

Orally disintegrating tablets

An orally disintegrating tablet can use mannitol, crospovidone, croscarmellose sodium, and a taste-masking system. The principal technical challenges are:

• Eletriptan hydrobromide's bitter or pharmaceutical taste.
• Dose loading at 20 mg and 40 mg.
• Mechanical fragility during packaging and transport.
• Moisture sensitivity.
• Rapid disintegration without excessive friability.
• Reliable content uniformity at the lower dose.

A mannitol-based direct-compression platform can improve mouthfeel and provide a cooling sensation. Crospovidone often supports rapid capillary wicking and low-residue disintegration. Taste masking may require polymer coating, ion-exchange resin complexation, cyclodextrin complexation, or a flavor system. Each approach can alter dissolution and must be evaluated against the reference profile.

Chewable or rapidly dispersible tablets

A chewable product could target patients who cannot swallow standard film-coated tablets. It would require tighter control of taste, grittiness, tablet hardness, and dose uniformity. The commercial opportunity is narrower than for an orally disintegrating tablet because migraine patients may prefer a dosage form that can be taken without chewing.

Nasal delivery

A nasal eletriptan product could provide a differentiated route for patients with vomiting or impaired oral absorption. It would face substantially higher development risk than a tablet because the product would require device, spray-pattern, droplet-size, preservative, microbiological, local-tolerability, and nasal deposition studies. A nasal product would likely be a new drug application or 505(b)(2) development rather than a conventional ANDA against Relpax tablets.

Combination products

A fixed-dose product combining eletriptan with an antiemetic or nonsteroidal anti-inflammatory drug could improve acute migraine management. The formulation would have to address:

• Different dose ratios.
• Chemical compatibility.
• Dissolution of multiple actives.
• Drug-drug interaction labeling.
• New clinical or bridging evidence.
• Existing patents covering the combination or method of use.

The commercial case depends on whether the combination offers clinically meaningful convenience or adherence value over separately administered products.

What FDA regulatory pathway applies to eletriptan products?

A conventional immediate-release generic tablet can generally be developed through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The product must demonstrate:

• Same active ingredient, strength, dosage form, route, and conditions of use as the reference product.
• Pharmaceutical equivalence.
• Bioequivalence.
• Compliance with current good manufacturing practice.
• Acceptable labeling and inactive-ingredient controls.

FDA's product-specific guidance and general bioequivalence guidance should govern study design and formulation changes.[2][3] For a conventional immediate-release tablet, a fasting oral bioequivalence study is likely central, with fed-state work considered where required by FDA or justified by product characteristics.

Key quality attributes

Attribute	Commercial importance
Assay and content uniformity	Critical at 20 mg because the dose is relatively low
Dissolution	Core ANDA risk; sensitive to particle size, lubricant level, and disintegrant selection
Disintegration	Important for immediate-release performance and ODT differentiation
Related substances	Requires control of API and degradation products
Water content	Relevant to tablet strength, dissolution, and stability
Hardness and friability	Important for coated and uncoated product integrity
Microbial quality	Required for oral solid dosage manufacturing
Stability	Supports expiration dating and packaging selection

Excipient changes should be assessed through formulation-development studies, comparative dissolution, impurity profiling, and stability work. For postapproval changes, FDA's SUPAC-IR framework remains relevant to immediate-release solid oral dosage forms.[4]

What patents protect eletriptan hydrobromide?

The principal historical protection for eletriptan arose from compound and pharmaceutical-use patents associated with Pfizer's development program. The original U.S. compound patent commonly associated with eletriptan is U.S. Patent No. 5,545,677. Its effective exclusivity period has ended, and eletriptan is now a mature generic product category.[5]

The commercial relevance of legacy patents is limited compared with the period before generic entry. Any product-specific launch assessment still requires review of the current FDA Orange Book, patent certifications, pediatric exclusivity, and any litigation or settlement terms associated with listed patents.[6]

Patent categories relevant to a new eletriptan product

Patent category	Relevance to conventional generic	Relevance to differentiated product
Compound patent	Historically decisive; generally expired	Low unless a new chemical entity or salt is claimed
Salt or crystal-form patent	May affect API sourcing or manufacturing	Potentially relevant to a new solid form
Tablet formulation patent	Usually limited if expired or absent	Relevant to ODT, taste masking, or novel excipient systems
Method-of-use patent	Can affect labeling and Paragraph IV strategy	Relevant to new patient populations or dosing regimens
Combination patent	Usually irrelevant to single-agent tablets	Relevant to fixed-dose migraine products
Manufacturing patent	Can restrict a particular process	Relevant where the process reduces impurities or improves yield
Device or delivery patent	Not relevant to ordinary tablets	Important for nasal, buccal, or other delivery systems

When does eletriptan lose exclusivity?

Eletriptan's principal small-molecule exclusivity period has already elapsed. Relpax received FDA approval in 2002, and the product's commercial exclusivity was followed by generic development and approval activity. Pediatric exclusivity, if applicable to the original product, does not create a current barrier to ordinary generic development.

The relevant current question is not whether the original branded product remains protected by basic compound exclusivity. It is whether any active, listed patent or regulatory exclusivity restricts a specific dosage form, indication, formulation, or launch date.

What is the Orange Book and Paragraph IV status of eletriptan?

The FDA Orange Book identifies approved drug products, therapeutic-equivalence evaluations, and applicable listed patents.[6] For a mature eletriptan tablet, a generic applicant typically evaluates whether to file:

• Paragraph I certification if no patent information is listed.
• Paragraph II certification if listed patents have expired.
• Paragraph III certification if the applicant will wait until patent expiry.
• Paragraph IV certification if the applicant asserts that a listed patent is invalid, unenforceable, or not infringed.

A Paragraph IV filing can trigger patent litigation under Hatch-Waxman. The litigation risk depends on the exact patent claims, the proposed label, the formulation, and the timing of the notice letter. For a differentiated ODT or combination product, the relevant patent analysis extends beyond the Orange Book to published applications, granted patents, and freedom-to-operate review across the United States, Europe, Canada, Japan, and major emerging markets.

Which companies are challenging or supplying eletriptan?

Eletriptan is supplied through a mature generic landscape rather than a single branded monopoly. FDA approval status and current marketing status should be checked by product and manufacturer in the Orange Book and Drugs@FDA because an approved ANDA is not always actively marketed.

Potential suppliers compete primarily on:

• API cost and dual sourcing.
• Tablet yield and compression speed.
• Packaging efficiency.
• Stability in high-temperature and high-humidity markets.
• Wholesale acquisition price.
• Retail and pharmacy-channel access.
• Ability to supply both 20 mg and 40 mg strengths.

The reference brand remains commercially relevant for brand-loyal patients and formulary positioning, but conventional tablet generics generally face substantial price competition.

How strong is the patent estate for a new eletriptan formulation?

A standard generic tablet has limited differentiation and usually a weak standalone patent position. A new product can improve its intellectual-property position by claiming a narrow technical feature that produces measurable value, such as:

• A specific orally disintegrating composition.
• A taste-masked eletriptan particle or resin complex.
• A defined dissolution profile tied to a manufacturing process.
• A novel crystalline or amorphous form with improved stability.
• A nasal formulation with specified spray performance.
• A fixed-dose combination and its method of use.

Patent strength depends on claim breadth, enablement, unexpected performance, freedom to practice, and the ability to show that the claimed feature is clinically or commercially meaningful. A formulation patent that merely substitutes one routine diluent for another is less defensible than a claim supported by comparative dissolution, stability, taste, or pharmacokinetic data.

What generic entry risks exist for eletriptan?

Generic entry risks are moderate for a conventional tablet and higher for differentiated dosage forms.

Risk	Standard tablet	ODT or novel formulation
API availability	Low to moderate	Moderate
Excipient supply	Low	Moderate
Bioequivalence failure	Moderate	High
Dissolution variability	Moderate	High
Patent litigation	Low to moderate	Moderate to high
Manufacturing scale-up	Low	Moderate
Commercial price erosion	High	Moderate
Regulatory complexity	Low	Moderate to high

The largest risk for a basic product is commercial rather than technical. Several suppliers can produce conventional immediate-release tablets, so price erosion and channel access determine returns. The largest risk for an ODT is proving that taste masking and rapid disintegration do not materially change exposure relative to the reference product.

Does eletriptan have biosimilar risk?

No. Eletriptan hydrobromide is a chemically synthesized small molecule, not a biologic. Biosimilar pathways do not apply. Competitive risk comes from generic ANDA products, 505(b)(2) reformulations, combination products, and other acute migraine therapies such as sumatriptan, rizatriptan, zolmitriptan, naratriptan, gepants, and ditans.

How does eletriptan compare with competing migraine products?

Product class	Advantages versus eletriptan	Limitations versus eletriptan
Sumatriptan	Broad dosage-form range, including nasal and injectable products	More extensive competition and tolerability differences
Rizatriptan	Rapidly disintegrating tablet availability	Drug-interaction and patient-selection considerations
Zolmitriptan	Oral and nasal options	Similar triptan-class restrictions
Naratriptan	Longer half-life in selected patients	Slower onset
Gepants	Useful for some patients unable to use triptans	Higher cost and different reimbursement dynamics
Ditans	Option where vasoconstrictive triptans are unsuitable	Sedation and driving restrictions may limit use

Eletriptan's commercial value is strongest where a manufacturer can combine competitive pricing with reliable supply and a convenience-oriented dosage form.

What are the main commercial opportunities?

The conventional generic opportunity is a scale and cost business. A supplier should prioritize high-yield compression, low-cost packaging, API dual sourcing, and reliable 20 mg and 40 mg availability.

The differentiated opportunity is narrower but potentially more defensible. An ODT or rapidly dispersible product could command a premium if it provides credible advantages during migraine attacks. The commercial package should include taste acceptability, rapid disintegration, moisture-resistant packaging, and clear patient instructions.

Geographic expansion is another opportunity. Markets with limited triptan access may favor local or regional manufacturing partnerships. Registration strategies should account for country-specific excipient restrictions, titanium dioxide policies, pharmacopoeial standards, stability zones, and trademark requirements.

Manufacturing barriers are limited for ordinary tablets. They increase when the product uses coated particles, resin complexes, specialized granulation, high-shear coating, or nasal-device filling. Those processes can create manufacturing know-how that functions as a practical barrier even when patent protection is narrow.

Key Takeaways

• Eletriptan hydrobromide is a mature small-molecule product with a relatively simple immediate-release tablet platform.
• The reference excipient system relies on lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide, and triacetin.
• A standard generic tablet has low technical complexity but high price-competition risk.
• The strongest formulation opportunity is an orally disintegrating or rapidly dispersible product with effective taste masking.
• A conventional ANDA is the most efficient regulatory route for an equivalent 20 mg or 40 mg tablet.
• New delivery systems, fixed-dose combinations, and novel formulations may require 505(b)(2) or NDA development.
• Original compound exclusivity and pediatric exclusivity are historical issues; current launch analysis should focus on active Orange Book patents and any formulation-specific rights.
• Eletriptan has no biosimilar risk because it is a synthetic small molecule.
• Commercial returns depend more on manufacturing cost, supply reliability, channel access, and dosage-form differentiation than on basic compound patent protection.

FAQs

What is the best excipient for an eletriptan orally disintegrating tablet?

Mannitol is a strong primary diluent for mouthfeel, while crospovidone or croscarmellose sodium can provide rapid disintegration. The final choice must account for taste, tablet strength, moisture sensitivity, and dissolution.

Can a generic eletriptan tablet use different excipients from Relpax?

Yes. A generic may use a different quantitative or qualitative excipient composition if it meets FDA requirements for inactive ingredients, pharmaceutical equivalence, bioequivalence, quality, and stability.

Is eletriptan hydrobromide suitable for a lactose-free product?

Yes. A lactose-free formulation can use microcrystalline cellulose, mannitol, or other appropriate diluents. The change may affect compression, disintegration, taste, and dissolution.

Would an eletriptan nasal spray qualify as a generic?

Usually not through a straightforward tablet ANDA. A nasal spray would likely require a different regulatory strategy, such as a 505(b)(2) application, supported by device, local-tolerability, performance, and clinical or pharmacokinetic data.

What is the most important commercial risk for generic eletriptan?

For a conventional tablet, the principal risk is rapid price erosion from multiple suppliers. For a differentiated product, the primary risks are bioequivalence, taste masking, stability, and the ability to justify a price premium.

References

1. U.S. Food and Drug Administration. (2023). Relpax (eletriptan hydrobromide) tablets prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2021). Bioavailability and bioequivalence studies submitted in NDAs or INDs: General considerations. FDA.

3. U.S. Food and Drug Administration. (2024). Product-specific guidance for generic drug development. FDA.

4. U.S. Food and Drug Administration. (1995). SUPAC-IR: Immediate-release solid oral dosage forms: Scale-up and postapproval changes. FDA.

5. U.S. Patent and Trademark Office. (1996). U.S. Patent No. 5,545,677: Pharmaceutical compounds. U.S. Department of Commerce.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.